20230222: A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in High Risk Subjects with Elevated Lipoprotein(a) (AMG 890)
Primary To evaluate the effect of olpasiran, compared to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction or urgent coronary revascularization in high-risk participants with elevated Lipoprotein(a) Key Secondary To evaluate the effect of olpasiran, compared to placebo, in high-risk participants with elevated lp(a) on the risk for: -Cardiovascular death, myocardial infarction or ischemic stroke -Cardiovascular death, myocardial infarction,urgent coronary revascularization or ischemic stroke To evaluate the effect of olpasiran, compared to placebo, in high-risk participants with elevated Lp(a) on change for baseline in Lp(a) Other Secondary: To evaluate the effect of olpasiran, campared to placebo, in high-risk participants with elevated Lp(a) on the risk for : Myocardial infarction CHD death or myocardial infarction Urgent coronary revascularization Coronary revascularization CHD death Cardiovascular death Death by any sause Ischemic stroke To evaluate the pharmacokinetics (PK) of Olpasiran in high-risk participants with elevated Lp(a) Safety To evaluate the safety and tolerability of olpasiran administered subcutaneously, compared to placebo, in high-risk participants with elevated Lp(a) Exploratory To evaluate the immunogenicity of Olpasiran in high-risk participants with elevated Lp(a)